Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO),
Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with a Variety of Treatments
New York, NY; Pt, Roberts, WA - April 7, 2016- Investorideas.com, a digital global news
source covering leading sectors including medical technology and biotech stocks
releases the following report on Glaucoma and public companies currently
involved in the treatment of the disease. Glaucoma is a
group of eye diseases which result in damage to the eye’s optic nerve and
left untreated will lead to vision loss and eventual blindness.
US Companies currently working on Glaucoma treatments
include Q BioMed Inc, (QBIO), Aerie Pharmaceuticals (AERI), Glaukos Corporation
(GKOS), Inotek (ITEK).
Internationally, NicOx SA (Paris: COX.PA) and
Santen Pharmaceuticals Co. Ltd. (Tokyo:4536) are leading the way with research
and development and treatment options for the disease.
Company
News:
On March 28, Aerie Pharmaceuticals (NasdaqGM:AERI)
issued a press release announcing the that dosing commenced of the first
patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial
of Roclatan™(netarsudil/latanoprost ophthalmic
solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its
ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular
hypertension.
The same day, Glaukos Corporation (NYSE:GKOS)
announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has
approved its iStent®
Trabecular Micro-Bypass Stent for use
in conjunction with cataract surgery for the reduction of intraocular pressure
(IOP) in adult patients diagnosed with mild to moderate open-angle glaucoma who
are currently treated with ocular hypotensive medication. The iStent is the first-ever ab interno Micro-Invasive
Glaucoma Surgery (MIGS) device approved for use in Japan.
Q BioMed Inc, (OTCQB:QBIO) expanded on the
company’s Corporate Update with a Q&A with Investorideas.com and a video
interview with StockNewsNow was also released.
In both interviews, President Denis Corin included the
Mannin Research Inc.
license agreement and the glaucoma eye drop treatment being developed by Dr. Susan Quaggin. Mannin Research’s (Mannin) Glaucoma
therapeutic is a first-in-class therapeutic designed to treat Primary
Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director
of the Feinberg Cardiovascular Research Institute and Chief of the Division of
Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic
is an important molecule in the context of new pharmaceuticals that can treat
Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in
the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a
main drainage path for the eye. Mannin is currently in the pre-clinical phase.
Optimizing the molecule, the aim is to use it in the clinic in late 2017/early
2018.
Sources: http://finance.yahoo.com/news/stocknewsnow-com-publishes-snnlive-video-123000560.html and http://finance.yahoo.com/news/president-q-biomed-inc-expands-120000146.html
In early March, Inotech Pharmaceutical Corporation
(NasdaqGM: ITEK) announced that it had strengthened the Patent Estate for its
lead drug candidate Trabodenoson, an investigational agent currently in pivotal
Phase 3 clinical trials for the treatment of glaucoma.
Source: https://finance.yahoo.com/news/inotek-pharmaceuticals-strengthens-patent-estate-120000301.html
In late February, NicOx SA (Paris: COX.PA) provided
a corporate update which included a report on its US FDA review for an IOP
(intraocular pressure) lowering singe-agent eye drop for patients with
open-angle glaucoma
Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC:
SNPHY) is focused on corneal disorders that lack effective treatment options and
on glaucoma and retinal disorders that are increasing in prevalence due to the
aging of society.
Novartis AG (NYSE:NVS) subsidiary Alcon, the global
leader in eye care and a division of Novartis released news in February of 2016
announcing that it had entered into an agreement to acquire Transcend Medical,
Inc., a privately-held, US-based company focused on developing
minimally-invasive surgical devices to treat glaucoma.
Pfizer Inc’s (NYSE:PFE) Ophthalmology Unit indicates that it is interested in “establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers” in a number of ophthalmological areas including glaucoma.
Acadia Pharmaceuticals Inc.’s (NasdaqGS:ACAD)
Muscarinic Program have discovered small-molecule product candidates for the
treatment of glaucoma. Using a proprietary discovery platform, they identified
a subtype of the muscarinic receptors that controls intraocular pressure and
discovered lead compounds that selectively activate this target.
The Market Outlook:
The global glaucoma surgical devices market is
expected to reach USD 3.11 billion by 2020, growing at a CAGR of close to 41%,
according to Technavio’s latest report.
TechNavio's analysts forecast the Global Glaucoma
Therapeutics market will grow at a CAGR of 2.53 percent over the period
2013-2018.
TechNavio's analysts forecast the Global Glaucoma
Devices market to grow at a CAGR of 20.72 percent over the period 2013-2018.
Q BioMed Inc.
("Q") is a biomedical acceleration and development company. We are
focused on acquiring companies and biomedical assets. Q is dedicated to
providing these target companies and assets, strategic resources, developmental
support, and expansion capital to ensure they meet their developmental
potential enabling them to provide products to patients in need.
Aerie is a clinical-stage pharmaceutical company
focused on the discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies
with novel mechanisms of action to treat patients with glaucoma and ocular
hypertension. It is expected that the NDA filing for Rhopressa™ (netarsudil ophthalmic solution) 0.02% will take place
in the third quarter of 2016. The second product candidate, Roclatan™ (netarsudil/latanoprost ophthalmic solution)
0.02%/0.005%, which is a fixed dose combination of Rhopressa™ and widely prescribed PGA latanoprost, currently has
two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If
these trials are successful, a Roclatan™ NDA filing
is expected to take place in the second half of 2017. In addition, Aerie is
further building its pipeline, including through research collaborations with
GrayBug, Inc. and Ramot at Tel Aviv University. http://www.aeriepharma.com/
Glaukos is an ophthalmic medical technology company
focused on the development and commercialization of breakthrough products and
procedures to transform the treatment of glaucoma, one of the world’s leading
causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or
MIGS, to revolutionize the traditional glaucoma treatment and management
paradigm. Glaukos launched the iStent® its first MIGS device, in the United States in July
2012 and is leveraging its platform technology to build a comprehensive and
proprietary portfolio of micro-scale injectable therapies designed to address
the complete range of glaucoma disease states and progression. http://www.glaukos.com/
Inotek is a
clinical-stage biopharmaceutical company focused on the discovery, development
and commercialization of therapies for glaucoma and other eye diseases. The
Company's lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development Trabodenoson was
developed in Inotek's laboratories and is designed to restore the eye's natural
pressure control mechanism. Additionally, the Company is evaluating the
potential for selective adenosine mimetics to address optic neuropathies and
other degenerative retinal diseases. http://www.inotekpharma.com/
NicOx is an international commercial-stage company
focused on the ophthalmic market. With a heritage of innovative R&D,
business development and marketing expertise, Nicox is building a diversified
portfolio of ophthalmic products that can help people enhance their sight.
Nicox's advanced pipeline features latanoprostene bunod for the lowering of
intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular
hypertension, and for which a New Drug Application (NDA) was submitted to the
FDA by the Company's licensee Valeant. The Company's pipeline also features
AC-170, a pre-NDA candidate for the treatment of ocular itching associated with
allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain
and inflammation after cataract surgery. Beyond these late-stage candidates,
Nicox is developing a pipeline of next generation ophthalmology-focused
candidates which utilize its proprietary nitric oxide (NO)-donating research
platform. The Group has operations in Europe and the United States.
About
Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com - digital media global
news source, PR and social media in leading sectors.
Sign up for free news alerts at
Investorideas.com
Disclaimer/Disclosure: Investorideas.com
is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investment involves risk and possible loss of investment. This site is
currently compensated for news publication and distribution, social media and
marketing, content creation and more. Contact each company directly regarding
content and press release questions. Disclosure is posted for each compensated
news release, content published /created if required but otherwise the news was
not compensated for and was published for the sole interest of our readers and
followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for
PR, media, news publication and social media effective February 5th for three
months: two thousand five hundred per month.
Additional info regarding BC Residents
and global Investors: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new disclosure
filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Contact
Investorideas.com
800 665 0411
